SCI时时刷

search
+
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Competing interests A.S.K. received research funding from AstraZeneca and ...
High WEE1 expression is independently linked to poor survival in multiple myeloma
High WEE1 expression is independently linked to poor survival in multiple myeloma
Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alteratio...
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Risk stratification models based on cytogenetics and disease burden help identify high-risk patients with newly diagnosed ...
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the o...
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a...
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
CBF-AMLs, which account for approximately 12–15% of all AML cases, involve c...
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective the...
Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4....
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Despite the considerable effort to characterize the genomic landscape of chronic lymphocytic leukemia (CLL), published dat...
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Response and progression criteria are necessary for any malignancy to standa...
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab
Accumulating evidence suggests that blinatumomab (a CD3-CD19 bispecific T-ce...
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
Anemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention
Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic str...
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier
Case presentationIn June 2021, a 32-year-old woman was admitted to the Emergency Department with a two-week history of ast...
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the ...
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome
GATA2 germline mutations lead to a syndrome characterized by immunodeficiency, vascular disorders and myeloid malignancies...
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with my...
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
Multiple myeloma (MM) flourishes within the bone marrow (BM), a metabolicall...
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intens...
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
Extramedullary disease (EMD) in multiple myeloma (MM) affects up to 20% of p...
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
The TRB repertoire was characterized in 137 samples, representing 59 patients from the HOVON-139/GIVE trial at trial entry...
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma
Competing interests The author discloses the following relationships: Cons...
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosoma...
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/ref...
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Competing interests F.M. reports honoraria from Therakos/Mallinckrodt, Jan...
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and rel...
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
To compare the efficacy and safety of gecacitinib (also known as jaktinib) with hydroxyurea (HU) in treating myelofibrosis...
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels
Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities a...
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a kind of aggressive T-cell lymphoma with significant enrichment of non-malig...
阅读更多
format_indent_increase